Affymax Announces Updates to Senior Leadership Team
PALO ALTO, Calif. -- February 1, 2013
Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Christine
Conroy, Pharm.D., to senior vice president, Regulatory Affairs and Quality
Assurance, as well as Tim Varacek to vice president, Sales and Account
Management. The company also announced Robert F. Venteicher, Ph.D., will
retire as Affymax’s senior vice president, technical operations effective
March 31, 2013.
“We have made remarkable strides with OMONTYS in the past year, securing
approval of this once-monthly erythropoiesis-stimulating agent and supporting
its successful launch,” said John Orwin, chief executive officer of Affymax.
“Christine played a critical role in our successful New Drug Application and
regulatory review of OMONTYS and has demonstrated continued leadership in
Corporate Quality and Regulatory Affairs as we transitioned to a
commercial-stage company. On the commercial front, Tim has been instrumental
in forging timely relationships with our key customers and leading our sales
team in their efforts. We are pleased to have Christine’s and Tim’s pertinent
experience and expertise on our senior management team.”
Dr. Conroy had served as vice president, Corporate Quality and Regulatory
Affairs for Affymax since December 2011. She served as vice president
Regulatory Affairs and Clinical Quality Assurance from July 2007 to November
2011, and she held positions with increasing levels of responsibility in
Regulatory Affairs from October 2004 to July 2007. Before joining Affymax, Dr.
Conroy held various senior level positions in the regulatory departments of
Genitope Corporation and Roche Global Development. She started her career in
the pharmaceutical industry in 1989 at Syntex Laboratories, Inc. in the
Medical Services Department. She earned her Pharm.D. from the University of
Kansas, School of Pharmacy, and her B.S. in pharmacy from the University of
Colorado, School of Pharmacy.
Mr. Varacek had served as executive director, Sales and Account Management for
Affymax since April 2011. Prior to joining Affymax, he served in various
executive roles in Sales Management, and from January 2007 through March 2011
was responsible for managing national accounts for Amgen’s nephrology
franchise. During his tenure at Amgen, he also served in various management
positions within Marketing and Sales Operations. Prior to Amgen, Mr. Varacek
held positions in Sales, Sales Management and Sales Training at Bristol-Myers
Squibb Inc. Mr. Varacek earned a B.S. in Biology from Binghamton University.
John Orwin continued, “I would also like to thank Bob for his significant
contributions throughout his close to six year tenure with the company. We
wish him well in his retirement.”
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California.
Affymax's mission is to discover, develop and deliver innovative therapies
that improve the lives of patients with kidney disease and other serious and
often life-threatening illnesses.
The company's first marketed product, OMONTYS® (peginesatide) Injection, was
approved by the U.S. Food and Drug Administration (FDA) in March 2012. For
additional information, please visit www.affymax.com.
This release contains forward-looking statements, including statements
regarding the potential of OMONTYS, the continuation and success of Affymax's
collaboration with Takeda Pharmaceuticals U.S.A., Inc. and the
commercialization of OMONTYS. Affymax's actual results may differ materially
from those indicated in these forward-looking statements due to risks and
uncertainties, including risks relating to the factors affecting the
commercial potential of OMONTYS, the continued safety and efficacy of OMONTYS,
industry and competitive environment, regulatory requirements by the FDA or
other regulatory authorities, including post-marketing studies, trials and
Risk Evaluation and Mitigation Strategy, the potential for disruptions to
supply, financing requirements and our ability to access capital and other
matters that are described in Affymax's Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission. Investors are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date of this release. Affymax undertakes no obligation to update any
forward-looking statement in this press release.
Sylvia Wheeler, 650-812-8861
Vice President, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.